Du är här

2015-10-13

aap: Q3/2015 sales with EUR 8.4 million (+7%) in line with expectations; strong quarter in Biomaterials business (+27%)

aap Implantate AG / aap: Q3/2015 sales with EUR 8.4 million (+7%) in line with
expectations; strongquarter in Biomaterials business (+27%) . Processed and
transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely
responsible for the content of this announcement.
aap
Implantate AG (XETRA: AAQ.DE) generated sales of EUR 8.4 million in the third
quarter of 2015 (Q3/2014: EUR 7.8 million) according to preliminary figures,
thereby achieving a result within the August forecast of EUR 7.5 million to
EUR 9.0 million. Sales in the first nine months of the current financial year
totalled EUR 22.0 million (9M/2014: EUR 22.1 million).

---------------------------------------------
| In EUR million Q3/2015 Q3/2014 Change |
| Sales 8.4 7.8 7% |
| Trauma 2.9 3.3 -14% |
| thereof LOQTEQ® 1.5 2.4 -37% |
| Biomaterials 5.4 4.2 27% |
| Projects 0.0 0.1 -92% |
| Other 0.1 0.2 -30% |
---------------------------------------------

---------------------------------------------
| In 9M/2015 9M/2014 Change |
|EUR million |
| Sales 22.0 22.1 0% |
| Trauma 8.5 8.4 1% |
| thereof LOQTEQ® 5.2 5.3 -2% |
| Biomaterials 13.0 12.7 2% |
| Projects 0.2 0.3 -25% |
| Other 0.3 0.7 -59% |
---------------------------------------------

In the trauma businessaap
Implantate AG reached sales of EUR 2.9 million (Q3/2014: EUR 3.3 million) in the third quarter of 2015. The background to this decline were various developments in our strategically important growth markets in the BRICS and SMIT countries which weighed perceptibly on demand. Crucial were in particular a significantly reduced willingness to invest in China as a consequence of the recent stock market crash and the devaluation of the Chinese currency, the continuing weak Rouble including the trade sanctions imposed against Russia as well as the increasing unfavourable development of the Euro/Turkish Lira exchange rate in connection with a reimbursement reduction already implemented at the beginning of the year. Furthermore the first shipments to Brazil which were planned for the third quarter could not be carried out due to delays in product approval.
Although customer interest inaap
Implantate AG's trauma portfolio remains intact, the company was unable to escape these external developments entirely. Furthermore, the US market has yet to make a significant contribution toward sales due to in part protracted administrative processes.
In contrast sales in the biomaterials business rose by 27% year-on-year in the third quarter of the current financial year to EUR 5.4 million (Q3/2014: EUR 4.2 million). The growth driver in the third quarter of 2015 was in particular the bone cement business with global leading companies.
In the first nine months of 2015,aap
Implantate AG's sales in the trauma business totalled EUR 8.5 million (9M/2014: EUR 8.4 million). In the biomaterials business sales totalled EUR 13.0 million (9M/2014: EUR 12.7 million) in the nine-month period 2015.
The preliminary results contained in this press release are based on management's initial analysis of operations for the period ended on 30 September 2015, and are therefore subject to change.aap
Implantate AG plans to announce its final results for the third quarter respectively the first nine months of 2015 on 13 November 2015.
Aboutaap
Implantate AG

aap Implantate AG is a globally operating medical device company headquartered
in Berlin, Germany. The company develops, manufactures and markets trauma and
biomaterials products for orthopedics. The trauma portfolio includes besides
the innovative anatomical plating system LOQTEQ® a wide range of cannulated
screws as well as standard plates and screws. In the biomaterials business
the company is specialized on bone cements and mixing systems. In
German-speaking countriesaap
Implantate AG directly sells its trauma products to hospitals, buying
syndicates and hospital groups while it uses a broad network of distributors
in more than 60 countries at the international level. In the biomaterials
business sales are handled via OEM and private label cooperations with
several selected international orthopedic and trauma companies.aap
Implantate AG's stock is listed in the Prime Standard segment of Frankfurt
Stock Exchange (XETRA: AAQ.DE). For more information, please visit
www.aap.de, or download the Company's investor relations app from the Apple's
App Store or Google Play.

Forward-looking statement

This release may contain forward-looking statements based on current
experience, estimates and projections of the management board and currently
available information. They are not guarantees of future performance. Various
known and unknown risks, uncertainties and other factors could lead to
material differences between the actual future results, financial situation,
development or performance of the company and the estimates given here. Many
factors could cause the actual results, performance or achievements of aap to
be materially different from those that may be expressed or implied by such
statements. These factors include those discussed inaap
's public reports. Forward-looking statements therefore speak only as of the
date they are made.aap
does not assume any obligation to update the forward-looking statements
contained in this release or to conform them to future events or
developments.

For inquiries please contact:aap
Implantate AG, Fabian Franke, Investor Relations, Lorenzweg 5, 12099 Berlin,
Germany

Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail: f.franke@aap.de

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: aap Implantate AG via Globenewswire

HUG#1958424

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.